Download

Full Text

• Ku GY, Ilson DH. Chemotherapeutic options for gastroesophageal junction tumors. Semin Radiat Oncol. 2013; 23 0(1): 24-30. doi: 10.1016/j. semradonc.2012.09.003
• Ilson DH. Cancer of the gastroesophageal junction: Current therapy options. Curr Treat Options Oncol. 2006; 7 (5): 410-23
• Schwartzberg LS, Vogel WH, Campen CJ. Methotrexate and Fluorouracil Toxicities: A Collaborative Practice Approach to Prevention and Treatment. The ASCO Post. 2014; 5 (7) (Supplement)
• Meta-Analysis Group in Cancer, Lévy E, Piedbois P, Buyse M, Pignon JP, Rougier P, Ryan L, Hansen R, Zee B, Weinerman B, Pater J, Leichman C, Macdonald J, et al. Toxicity of fluorouracil in patients with advancedcolorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol. 1998; 16 (11): 3537-41
• Van Staveren MC, Guchelaar HJ, van Kuilenburg AB, Gelderblom H, Maring JG. Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. Pharmacogenomics J. 2013; 13 (5): 389-95. doi: 10.1038/tpj.2013.25
• Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, Kerb R, Blievernicht J, Fischer J, Hofmann U, Bokemeyer C, Eichelbaum M; German 5-FU Toxicity Study Group. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol. 2008; 26 (13): 2131-8. doi: 10.1200/JCO.2006.10.4182
• Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003; 3 (5): 330-8
• Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer. 1991; 68 (3): 499-501
• Lyss, A P, Lilenbaum, RC, Harries BE, Diasio RB. Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. Cancer Invest. 1993; 11 (2): 239-40
• Leung HW, Chan AL. Association and prediction of severe 5-fluorouracil toxicity with dihydropyrimidine dehydrogenase gene polymorphisms: A meta-analysis. Biomed Rep. 2015; 3 (6): 879-83
• Meulendijks D, Henricks LM, Sonke GS, Deneen MJ, Froehlich TK, Amstutz U, Largiadèr CR, Jennings BA, Marinaki AM, Sanderson JD, Kleibl Z, Kleiblova P, Schwab M, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015; 16 (16): 1639-50. doi: 10.1016/S1470-2045(15)00286-7
• Toffoli G, Giodini L, Buonadonna A, Berretta M, De Paoli A, Scalone S, Miolo G, Mini E, Nobili S, Lonardi S, Pella N, Lo Re G, Montico M, et al. Clinical validity of a DPYDbased pharmacogenetic test to predict severe toxicity to fluoropyrimidines. Int J Cancer. 2015; 137 (12): 2971-80. doi: 10.1002/ijc.29654
• Lee AM, Shi Q, Pavey E, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Goldberg RM, Diasio RB. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. 2014; 106 (12). pii: dju298. doi: 10.1093/jnci/dju298
• Rosmarin D, Palles C, Pagnamenta A, Kaur K, Pita G, Martin M, Domingo E, Jones A, Howarth K, Freeman-Mills L, Johnstone E, Wang H, Love S, et al. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. Gut. 2015; 64 (1): 111-20. doi: 10.1136/gutjnl-2013-306571
• Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, Smits PH, Rosing H, Mandigers CM, Soesan M, Beijnen JH, Schellens JH. Upfronf genotyping of DPYD*2° to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol. 2016; 34 (3): 227-34. doi: 10.1200/JCO.2015.63.1325
• Seck K, Riemer S, Kates R, Ullrich T, Lutz V, Harbeck N, Schmitt M, Kiechle M, Diasio R, Gross E. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin Cancer Res. 2005; 11 (16): 5886-92
• Marcuello E, Altes A, Menoyo A, Rio ED, Baiget M. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidinebased chemotherapy? Cancer Chemother Pharmacol. 2006; 57 (6): 835-40
• Sharma R, Hoskins JM, Rivory LP, Zucknick M, London R, Liddle C, Clarke SJ. Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphisms and Toxicity to Capecitabine in Advanced Colorectal Cancer Patients. Clin Cancer Res. 2008; 14 (3): 817-25
• Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol. 2005; 23 (7): 1365-9
• Etienne-Grimaldi M-C, Francoual M, Formento JL, Milano G. Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer. Pharmacogenomics. 2007; 8 (11): 1561-6
• Loganayagam A, Arenas Hernandez M, Corrigan A, Fairbanks L, Lewis CM, Harper P, Maisey N, Ross P, Sanderson JD, Marinaki AM. Pharmacogenetic variants in the DYPD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer. 2013; 108 (12): 2505-15. doi: 10.1038/bjc.2013.262
• Rosmarin D, Palles C, Church D, Domingo E, Jones A, Jonhstone, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol. 2014; 32 (10): 1031-39. doi: 10.1200/JCO.2013.51.1857
• Afzal S, Gusella M, Vainer B, Vogel UB, Andersen JT, Broedbaek K, Petersen M, Jimenez-Solem E, Bertolaso L, Barile C, Padrini R, Pasini F, Jensen SA, et al. Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients. Clin Cancer Res. 2011; 17 (11):3822-3829. doi: 10.1158/1078-0432.CCR-11-0304
• Huang K, Shen Y, Zhang F, Wang S, Wei X. Evaluation of effects of thymidylate synthase and excision repair crosscomplementing 1 polymorphism on chemotherapy outcome in patients with gastrointestinal tumors using peripheral venous blood. Oncol Lett. 2016; 11 (5): 3477-82
• Wu NC, Su SM, Lin TJ, Chin J, Hou CF, Yang JY, Liu WS, Chang LC. Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and fluorouracil-based treatment in Taiwan colorectal cancer. Anticancer Drugs. 2015; 26 (8): 888-93. doi: 10.1097/CAD.0000000000000261
• Yhim HY, Cho SH, Kim SY, Cho IS, Lee KT, Lee WS, Lee SI, Park MR, Park SG, Han HS, Choi YS, Chung IJ, Shim HJ, et al. Prognostic implications of thymidylate synthase gene polymorphisms in patients with advanced small bowel adenocarcinoma treated with first-line fluoropyrimidinebased chemotherapy. Oncol Rep. 2015; 34 (1): 155-64
• Rumiato E, Boldrin E, Amadori A, Saggioro D. DMET (Drug-Metabolizing Enzymes and Transporters) microarray analysis of colorectal cancer patients with severe 5-fluorouracil-induced toxicity. Cancer Chemother Pharmacol. 2013; 72 (2): 483-8. doi: 10.1007/s00280-013-2210-1
• Magdy T, Arlanov R, Winter S, Lang T, Klein K, Toyoda Y, Ishikawa T, Schwab M, Zanger UM. ABCC11/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression. Pharmacogenomics. 2013; 14 (12): 1433-48. doi: 10.2217/pgs.13.139
• Lostia AM, Lionetto L, Ialongo C, Gentile G, Viterbo A, Malaguti P, Paris I, Marchetti L, Marchetti P, De Blasi A, Simmaco M. A liquid chromatography-tandem mass spectrometry method for the determination of 5-Fluorouracil degradation rate by intact peripheral blood mononuclear cells. Ther Drug Monit. 2009; 31 (4): 482-8. doi: 10.1097/FTD.0b013e3181ae4516
• Mazzuca F, Borro M, Botticelli A, Mazzotti E, Marchetti L, Gentile G, La Torre M, Lionetto L, Simmaco M, Marchetti P. Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort. Oncotarget. 2016 7 (15): 20612-20. doi: 10.18632/oncotarget.7991
• Gentile G, Botticelli A, Lionetto L, Mazzuca F, Simmaco M, Marchetti P, Borro M. Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction. Pharmacogenomics J. 2015; 16 (4): 320-5. doi: 10.1038/tpj.2015.56
• http://ecog-acrin.org/resources/ecog-performance-status Accessed September 22nd 2015
• Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003; 13 (3):176-81
• Solé X, Guinó E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006; 22 (15): 1928-9
• Rich TA, Shepard RC, Mosley ST. Four decades of continuing innovation with fluorouracil: Current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol. 2004; 22 (11): 2214-32
• Tsunoda A, Nakao K, Watanabe M, Matsui N, Ooyama A, Kusano M. Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study. Ann Oncol. 2011; 22 (2): 355-61. doi: 10.1093/annonc/mdq358
• Furuse H, Hirano Y, Harada M, Ming LH, Aoki T, Kurita Y, Mugiya S, Ushiyama T, Ozono S. Significance of 5-fluorouracil-related enzyme activities in predicting sensitivity to 5-fluorouracil in bladder carcinoma. Anticancer Res. 2009; 29 (4): 1001-8
• Ochiai T, Umeki M, Miyake H, Iida T, Okumura M, Ohno K, Sakamoto M, Miyoshi N, Takahashi M, Tsumura H, Tokunaga Y, Naitou H, Fukui T. Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer. Oncol Rep. 2014; 32 (3): 887-92 doi: 10.3892/or.2014.3299
• Sakamoto E, Nagase H, Kobunai T, Oie S, Oka T, Fukushima M, Oka T. Orotate phosphoribosyltrasferase expression level in tumors is a potential determinant of the efficacy of 5-fluorouracil. Biochem Biophys Res Commun. 2007; 363 (1): 216-22
• Botticelli A, Mazzuca F, Borro M, Mazzotti E, Maddalena C, Gentile G, Lionetto M, Simmaco P, Marchetti P. 2171 Effect of degradation rate of 5-FU and genetic polymorphisms of DPYD, TSER and MTHFR on toxicity of capecitabine in colorectal cancer. Eur J Cancer. 2015; 51 (Suppl 3): S390